Shah Pritesh's Form 4 filing
NovoCure Ltd (NVCR) · filed Mar 6, 2023
- Accession no.
- 0001562180-23-002492
- Filed
- Mar 6, 2023
- Trade date
- Mar 2-3, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market sales total $70.5K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Shah PriteshCIK 0001744884 | Officer (Chief Growth Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 2, 2023 | Ordinary Shares | SSaleDisposed | −937 | $75.28 | −$70,537.36 | 99,038 | Direct | |
| Mar 3, 2023 | Ordinary Shares | AGrant or awardAcquired | +3,936 | $0.00 | $0 | 102,974 | Direct | |
| Mar 3, 2023 | Ordinary Shares | AGrant or awardAcquired | +43,246 | $0.00 | $0 | 146,220 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.